Wang Xiaohua, Wang Zhen, Fu Jingshu, Huang Ke, Xie Zhao
National & Regional United Engineering Laboratory of Tissue Engineering, Department of Orthopaedics, Southwest Hospital, Third Military Medical University, Chongqing, 400038, People's Republic of China.
BMC Musculoskelet Disord. 2017 Jan 23;18(1):33. doi: 10.1186/s12891-017-1395-6.
Chronic hematogenous osteomyelitis often results from the improper treatment of acute hematogenous osteomyelitis. At present, there is lack of uniform standards for the treatment, and the clinical features of the disease are unclear. The purpose of this study was to explore the clinical efficacy and complications of chronic hematogenous tibia osteomyelitis treated with the induced membrane technique.
A retrospective analysis of the chronic hematogenous tibia osteomyelitis patients in our department admitted from January 2013 to February 2014 and treated with the induced membrane two-stage surgical technique was performed. The defects were filled with antibiotic-loaded polymethyl methacrylate (PMMA) cement after radical debridement, and bone grafts were implanted to repair the defects after 6 to 8 weeks.
A total of 15 cases were admitted in this study, including 13 men and 2 women with a mean age of 34 years (6 to 51). The mean duration of bone infection was 142 months (3 to 361). All patients were cured with an average follow-up of 25 months (24 to 28). Radiographic bone union occurred in 5.3 months (3 to 8), and full weight bearing occurred in 6.7 months (4 to 10). No recurrence of infection was noted at the last follow-up. Two cases required repeated debridement before grafting due to recurrent infection. One patient had a small bone diameter due to insufficient grafting, and one patient had limitation of knee activity.
The induced membrane technique for the treatment of chronic hematogenous tibia osteomyelitis is an effective and reliable method. Thorough debridement and wound closure at the first stage is essential for infection control as well as sufficient grafting at the second stage to ensure bone union.
慢性血源性骨髓炎常因急性血源性骨髓炎治疗不当所致。目前,该病治疗缺乏统一标准,其临床特征尚不明确。本研究旨在探讨采用诱导膜技术治疗慢性血源性胫骨骨髓炎的临床疗效及并发症。
回顾性分析2013年1月至2014年2月在我科收治的采用诱导膜两阶段手术技术治疗的慢性血源性胫骨骨髓炎患者。彻底清创后,用含抗生素的聚甲基丙烯酸甲酯(PMMA)骨水泥填充骨缺损,6至8周后植入骨移植材料修复缺损。
本研究共纳入15例患者,其中男性13例,女性2例,平均年龄34岁(6至51岁)。骨感染平均病程为142个月(3至361个月)。所有患者均治愈,平均随访25个月(24至28个月)。影像学检查显示骨愈合时间为5.3个月(3至8个月),完全负重时间为6.7个月(4至10个月)。末次随访时未见感染复发。2例患者因感染复发在植骨前需再次清创。1例患者因植骨不足导致骨直径较小,1例患者存在膝关节活动受限。
诱导膜技术治疗慢性血源性胫骨骨髓炎是一种有效且可靠的方法。一期彻底清创和伤口闭合对于控制感染至关重要,二期充足的植骨对于确保骨愈合也很关键。